Xeroderma pigmentosum (XP) is diagnosed through a combination of clinical evaluation and specialized laboratory testing. There are no routine blood tests or imaging scans that can confirm it. Instead, diagnosis relies on recognizing characteristic skin reactions to sunlight, followed by either a DNA repair assay performed on skin cells or genetic sequencing to identify the specific gene mutation involved.
Early Signs That Raise Suspicion
XP symptoms typically appear in early childhood, often before age two. The hallmark is an extreme reaction to sunlight: severe sunburns after minimal UV exposure, blistering, and early freckling on sun-exposed areas of skin. These reactions are far more intense than what you’d expect based on a child’s skin tone or the amount of time spent outdoors. Parents often notice something is wrong after a single brief outdoor outing causes a disproportionately bad burn that takes days to heal.
Eye problems frequently accompany the skin symptoms. Children may develop pronounced light sensitivity, corneal clouding, or eyelid swelling. Some forms of XP also involve neurological problems, including hearing loss, difficulty with coordination, or developmental delays, though not all subtypes cause these issues.
Minimal Erythema Dose Testing
One of the first clinical steps when XP is suspected is measuring how the skin responds to controlled UV exposure. This is called minimal erythema dose (MED) testing. Small patches of skin are exposed to UV light at increasing durations, then examined 24 to 48 hours later for redness. The shortest exposure that produces visible redness defines the MED. In people with XP, the threshold for burning is abnormally low, and the redness often persists much longer than expected. While this test doesn’t confirm XP on its own, it provides objective evidence of unusual photosensitivity and helps guide further testing.
The DNA Repair Assay
The gold standard for confirming XP has traditionally been the unscheduled DNA synthesis (UDS) assay. This test directly measures how well a person’s cells can repair UV damage to their DNA, which is the core defect in XP.
Here’s how it works: a small skin sample is taken, and fibroblasts (connective tissue cells) are grown in the lab. These cultured cells are then exposed to UV light, which creates specific types of DNA damage. The cells are given time to repair themselves in the presence of a radioactively labeled building block of DNA. As cells repair the UV damage, they incorporate this labeled material into the repaired strands. The more repair happening, the more radioactive material gets incorporated. Technicians then count the radioactive signals under a microscope. If the level of DNA repair activity is significantly low compared to normal cells, the diagnosis of XP is confirmed.
One subtype, called XP variant (XP-V), requires an extra step. Cells from people with XP-V don’t show the same dramatic UV sensitivity in standard culture conditions as the other subtypes (XP-A through XP-G). To detect XP-V, the lab incubates the fibroblasts with caffeine for several days after UV exposure. Caffeine blocks a backup DNA replication pathway these cells rely on, unmasking their repair deficiency. If UV sensitivity only appears after caffeine treatment, XP-V is confirmed.
Genetic Testing
Genetic sequencing has become increasingly central to XP diagnosis, both for confirming the condition and for identifying the exact subtype. Next-generation sequencing panels now cover all nine genes associated with XP: XPA, XPC, DDB2, ERCC2, ERCC3, ERCC4, ERCC5, ERCC1, and POLH. Each gene corresponds to a different complementation group (XP-A through XP-G, plus the variant type), and knowing which gene is affected matters because the subtypes carry different risks. Some are more likely to involve neurological decline, while others primarily affect the skin and eyes.
More than half of all XP cases in the United States involve mutations in just three of these genes: XPC, ERCC2, and POLH. The remaining genes each account for a smaller share of cases.
An older method called complementation analysis can also identify the subtype. In this test, fibroblasts from the patient are fused in the lab with cells from known XP subtypes. If the fused cells still show low DNA repair activity, the patient’s cells share the same genetic defect as the reference cells, pinpointing the complementation group. This technique is now largely supplemented by direct gene sequencing, which is faster and more widely available.
Skin Biopsy Findings
Skin biopsies in XP patients don’t diagnose the condition by themselves, but they reveal characteristic damage patterns. Under the microscope, affected skin typically shows thickening of the outer skin layer (hyperkeratosis), chronic inflammatory cells in the underlying tissue, and a notable increase in pigment-producing cells and melanin deposits in the deepest layer of the epidermis. These findings reflect the cumulative UV damage that XP skin cannot properly repair. Biopsies are more commonly used to evaluate suspicious lesions for skin cancer, which XP patients develop at dramatically elevated rates starting in childhood.
Prenatal Diagnosis for At-Risk Families
Families who already have a child with XP or who carry known mutations can pursue prenatal testing in subsequent pregnancies. Two approaches are available. The first uses the same UDS assay described above, performed on cells collected through amniocentesis or chorionic villus sampling (CVS). Cells are cultured and tested for UV-induced DNA repair activity, with results typically available about 25 days after the sample is collected. A study of 76 at-risk pregnancies using this method successfully identified 19 affected fetuses across both amniocentesis and CVS samples, confirming it as a reliable approach.
The second option is genetic sequencing of fetal cells, which is practical when the family’s specific mutations are already known. This can be performed on either chorionic villus cells or amniotic fluid cells and is generally faster than the repair assay.
Conditions That Look Similar
Several other genetic conditions cause unusual sun sensitivity and can be confused with XP early on. Cockayne syndrome involves photosensitivity and progressive neurological problems but typically does not increase skin cancer risk the way XP does. Some patients have an overlap condition called XP/Cockayne syndrome complex, where features of both disorders appear together. Rothmund-Thomson syndrome causes sun-sensitive rashes and skin changes but follows a different pattern. Hartnup disorder, a metabolic condition, and Carney complex can also produce photosensitivity that initially mimics XP. Distinguishing between these conditions is one reason the DNA repair assay and genetic testing are so important: clinical features alone can overlap significantly, but the underlying repair defect and gene mutations are specific to XP.